Chemotherapy dosing in overweight and obese patients with cancer (Q38121735)

29 August 2017

Chemotherapy dosing in overweight and obese patients with cancer (English)

1 reference

29 August 2017

0 references

1 reference

2

Alex Sparreboom

1 reference

29 August 2017

Gary H Lyman

1

1 reference

PubMed ID

23856744

29 August 2017

language of work or name

English

0 references

publication date

16 July 2013

1 reference

Nature Reviews Clinical Oncology

29 August 2017

1 reference

29 August 2017

10

1 reference

29 August 2017

8

1 reference

29 August 2017

451-459

1 reference

Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study

29 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dose translation from animal to human studies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Is dose normalization to weight or body surface area useful in adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Health and economic burden of the projected obesity trends in the USA and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Abdominal obesity and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Obesity and ovarian cancer survival: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Racial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Weight-based chemotherapy dosing in obese patients with cancer: back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Description of current practices of empiric chemotherapy dose adjustment in obese adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Obesity and therapy-related toxicity in patients treated for small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Effect of obesity on the pharmacokinetics of drugs in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

What is the best size descriptor to use for pharmacokinetic studies in the obese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dosing in obesity: a simple solution to a big problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Influence of lean body weight on anticancer drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Race/ethnic issues in obesity and obesity-related comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Undertreatment of obese women receiving breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Impact of chemotherapy dose intensity on cancer patient outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dose: a critical factor in cancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Kinetics of mammary tumor cell growth and implications for therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Growth Curve of an Experimental Solid Tumor Following Radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Advances in chemotherapy of cancer in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

The importance of dose intensity in chemotherapy of metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Effect of obesity on prognosis after early-stage breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Comparative effectiveness research in oncology: the need for clarity, transparency and vision

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

Comparative effectiveness research in oncology: an overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.108

The impact of obesity and disease on busulfan oral clearance in adults

31 March 2020

1 reference

12 December 2020

Experimental studies with actinomycin D

1 reference

12 December 2020

Simplified calculation of body-surface area.

1 reference

12 December 2020

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate

1 reference

12 December 2020

Neutropenia-wise and pound-foolish: safe and effective chemotherapy in massively obese patients

1 reference

12 December 2020

REACH 2010 Surveillance for Health Status in Minority Communities --- United States, 2001--2002.

1 reference

12 December 2020

Influence of obesity on drug disposition

1 reference

12 December 2020

Estimation of human body surface area from height and weight

1 reference

12 December 2020

The use of body surface area as a criterion of drug dosage in cancer chemotherapy.

1 reference

12 December 2020

The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors

1 reference

12 December 2020

Tumor size, sensitivity to therapy, and design of treatment schedules

1 reference

12 December 2020

The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

1 reference

12 December 2020

10.1038/NRCLINONC.2013.108

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23856744